The pharmacologic and clinical properties of Oxis® (formoterol) Turbuhaler®

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 53, Issue SUPPL. 42, 1998, Pages 14-19

  Selroos, O ^a  

^a Department of Clinical Research and Development ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FORMOTEROL; SALMETEROL; TERBUTALINE; UNCLASSIFIED DRUG;

ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HEADACHE; HEART PALPITATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; MUSCLE CRAMP; POWDER INHALER; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ASTHMA; BRONCHODILATOR AGENTS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; HUMANS;

EID: 0031946278     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.1998.tb04888.x     Document Type: Article

References (11)

1. Faulds D, Hollingshead LM, Goa KL. Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991 ;42: 11 5-37
2. 2adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy 1989;44:264-71.
3. Wetterlin K. Turbuhaler® - a new powder inhaler for administration of drugs to the airways. Pharmacol Res 1988;5:506-8
4. Ringdal N, Derom E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler' in mild to moderate asthma. Eur Respir J 1995;8:68s.
5. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10:2484-9.
6. Schreurs AJ, Sinninghe Damste HE, de Graaff CS, Greefhorst AP. A dose-response study with formoterol Turbuhaler' as maintenance therapy in asthmatic patients. Eur Respir J 1996;9:1678-83.
7. Brusasco V, Ringdal N, Ekstrom T, Sobradillo V. Effect of formoterol 6 mcg b.i.d. via Turbuhaler' for 3 months in asthma: comparison with terbutaline and placebo. Eur Respir J 1995;8 Suppl 19:158s.
8. Ekstrom T, Ringdal N, Tuluainen P. Formoterol Turbuhaler' 12 pg b.i.d. improves lung function in asthmatic patients compared with terbutaline and placebo. Eur Respir J 1995; 8 Suppl 19157s.
9. van der Molen T, Postma DS, Tbrner MO, et al. Effects of the long-acting P-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997;52:535-9
10. Lotvall J, Persson G, Larsson P, Mardell C, Rosenborg J. Tolerability of inhaled high doses of formoterol and salbutamol in asthmatic patients maintained on twice daily formoterol 12 pg (9 pg delivered). Eur Respir J 1997;10 Suppl 25:103s.
11. Falck M, Huhti L, Sutinen E, et al. Formoterol Turbuhaler' 72 and 120 pg (delivered doses 54 and 90 pg, respectively) daily during three days was safe in patients with asthma. Eur Respir J 1997;lO Suppl 25:103s.